Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.

Weissenrieder JS, Reed JL, Green MV, Moldovan GL, Koubek EJ, Neighbors JD, Hohl RJ.

Pharmacology. 2019 Oct 23:1-9. doi: 10.1159/000502562. [Epub ahead of print]

2.

Increased flux through the mevalonate pathway mediates fibrotic repair without injury.

Larson-Casey JL, Vaid M, Gu L, He C, Cai GQ, Ding Q, Davis D, Berryhill TF, Wilson LS, Barnes S, Neighbors JD, Hohl RJ, Zimmerman KA, Yoder BK, Longhini ALF, Hanumanthu VS, Surolia R, Antony VB, Carter AB.

J Clin Invest. 2019 Nov 1;129(11):4962-4978. doi: 10.1172/JCI127959.

3.

Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.

Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H.

Br J Haematol. 2019 Oct 1. doi: 10.1111/bjh.16228. [Epub ahead of print]

PMID:
31573077
4.

Cancer and the Dopamine D2 Receptor: A Pharmacological Perspective.

Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ.

J Pharmacol Exp Ther. 2019 Jul;370(1):111-126. doi: 10.1124/jpet.119.256818. Epub 2019 Apr 18.

PMID:
31000578
5.

Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity.

Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD.

Oncoimmunology. 2018 Nov 11;8(2):e1539614. doi: 10.1080/2162402X.2018.1539614. eCollection 2019.

6.

Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia.

Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Shike H, Bayerl MG, Sivik JM, Schell TD, Drabick JJ, Hohl RJ, Zheng H.

Cancer Res. 2019 Apr 1;79(7):1635-1645. doi: 10.1158/0008-5472.CAN-18-3107. Epub 2019 Feb 1.

PMID:
30709927
7.

Brain cholesterol metabolism and Parkinson's disease.

Huang X, Sterling NW, Du G, Sun D, Stetter C, Kong L, Zhu Y, Neighbors J, Lewis MM, Chen H, Hohl RJ, Mailman RB.

Mov Disord. 2019 Mar;34(3):386-395. doi: 10.1002/mds.27609. Epub 2019 Jan 25.

PMID:
30681742
8.

Schweinfurthins: Lipid Modulators with Promising Anticancer Activity.

Koubek EJ, Weissenrieder JS, Neighbors JD, Hohl RJ.

Lipids. 2018 Aug;53(8):767-784. doi: 10.1002/lipd.12088. Epub 2018 Oct 17. Review.

PMID:
30334267
9.

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H.

Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.

10.

Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.

Weissenrieder JS, Reilly JE, Neighbors JD, Hohl RJ.

Prostate. 2019 Jan;79(1):21-30. doi: 10.1002/pros.23707. Epub 2018 Aug 14.

PMID:
30106164
11.

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H.

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4. No abstract available.

12.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Kauffman EPS, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Aug 14;32(2):268. doi: 10.1016/j.ccell.2017.07.008. No abstract available.

13.

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.

14.

Cancer Therapy: Shooting for the Moon.

Lee J, Blumenthal GM, Hohl RJ, Huang SM.

Clin Pharmacol Ther. 2017 May;101(5):552-558. doi: 10.1002/cpt.655. No abstract available.

15.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.

16.

Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis.

Reilly JE, Neighbors JD, Hohl RJ.

Cancer Biol Ther. 2017 Nov 2;18(11):872-882. doi: 10.1080/15384047.2016.1219817. Epub 2016 Sep 13.

17.

GBM-associated mutations and altered protein expression are more common in young patients.

Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB.

Oncotarget. 2016 Oct 25;7(43):69466-69478. doi: 10.18632/oncotarget.11617.

18.

Anticoagulants: Major Advances Without Clear Consensus.

Hohl RJ.

Clin Pharmacol Ther. 2016 Aug;100(2):116-8. doi: 10.1002/cpt.399.

PMID:
27393187
19.

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.

Raje NS, Faber EA Jr, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC.

Clin Cancer Res. 2016 Dec 1;22(23):5688-5695. Epub 2016 Jun 10.

20.

3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines.

Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ.

Lipids. 2015 Dec;50(12):1195-207. doi: 10.1007/s11745-015-4083-z. Epub 2015 Oct 22.

21.

Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.

Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ.

Clin Exp Metastasis. 2015 Aug;32(6):555-66. doi: 10.1007/s10585-015-9727-0. Epub 2015 Jun 13.

22.

Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil.

Sheehy RM, Kuder CH, Bachman Z, Hohl RJ.

Cancer Biol Ther. 2015;16(8):1259-68. doi: 10.1080/15384047.2015.1056420. Epub 2015 Jun 5.

23.

In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.

Reilly JE, Zhou X, Tong H, Kuder CH, Wiemer DF, Hohl RJ.

Biochem Pharmacol. 2015 Jul 15;96(2):83-92. doi: 10.1016/j.bcp.2015.04.009. Epub 2015 May 4.

24.

Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.

Ferguson NN, Thomas CP, Hohl RJ, Syrbu SI, Stone MS, Wanat KA.

Am J Dermatopathol. 2015 Oct;37(10):790-4. doi: 10.1097/DAD.0000000000000272. Review.

PMID:
25747810
25.

Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.

Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ.

Invest New Drugs. 2015 Jun;33(3):594-602. doi: 10.1007/s10637-015-0220-z. Epub 2015 Feb 21.

PMID:
25698442
26.

Oncology trial design: More accurately and efficiently advancing the field.

Hohl RJ.

Clin Pharmacol Ther. 2015 May;97(5):430-2. doi: 10.1002/cpt.94. No abstract available.

PMID:
25684240
27.

Drug development (and academic medicine): charting the course forward.

Hohl RJ.

Clin Pharmacol Ther. 2014 Nov;96(5):519-22. doi: 10.1038/clpt.2014.171.

PMID:
25336261
28.

Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase.

Zhou X, Reilly JE, Loerch KA, Hohl RJ, Wiemer DF.

Beilstein J Org Chem. 2014 Jul 18;10:1645-50. doi: 10.3762/bjoc.10.171. eCollection 2014.

29.

Personalized medicine: through the looking glass of functional imaging.

Hohl RJ.

Clin Cancer Res. 2013 Aug 1;19(15):4024-6. doi: 10.1158/1078-0432.CCR-13-1129. Epub 2013 Jun 19.

30.

Quantitative determination of isopentenyl diphosphate in cultured mammalian cells.

Tong H, Kuder CH, Wasko BM, Hohl RJ.

Anal Biochem. 2013 Feb 1;433(1):36-42. doi: 10.1016/j.ab.2012.09.001. Epub 2012 Sep 19.

PMID:
23000003
31.

Is there a future for prenyltransferase inhibitors in cancer therapy?

Holstein SA, Hohl RJ.

Curr Opin Pharmacol. 2012 Dec;12(6):704-9. doi: 10.1016/j.coph.2012.06.013. Epub 2012 Jul 18. Review.

PMID:
22817869
32.

Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification.

Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ.

Mol Pharmacol. 2012 Jul;82(1):9-16. doi: 10.1124/mol.111.077107. Epub 2012 Mar 29.

33.

Therapeutic additions and possible deletions in oncology in 2011.

Holstein SA, Hohl RJ.

Clin Pharmacol Ther. 2012 Jan;91(1):15-7. doi: 10.1038/clpt.2011.288. Review.

34.

Geranylgeranyl diphosphate synthase: an emerging therapeutic target.

Wiemer AJ, Wiemer DF, Hohl RJ.

Clin Pharmacol Ther. 2011 Dec;90(6):804-12. doi: 10.1038/clpt.2011.215. Epub 2011 Nov 2. Review.

PMID:
22048229
35.

Geranylgeranyl pyrophosphate stimulates PPARγ expression and adipogenesis through the inhibition of osteoblast differentiation.

Weivoda MM, Hohl RJ.

Bone. 2012 Feb;50(2):467-76. doi: 10.1016/j.bone.2011.09.056. Epub 2011 Oct 14.

PMID:
22019459
36.

A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.

Wasko BM, Smits JP, Shull LW, Wiemer DF, Hohl RJ.

J Lipid Res. 2011 Nov;52(11):1957-64. doi: 10.1194/jlr.M016089. Epub 2011 Sep 8.

37.

Clinical pharmacology as a foundation for translational science.

Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A.

Clin Pharmacol Ther. 2011 Jul;90(1):10-3. doi: 10.1038/clpt.2011.80. No abstract available.

PMID:
21691266
38.

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Pérez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, Blay JY.

Ann Oncol. 2012 Mar;23(3):771-6. doi: 10.1093/annonc/mdr265. Epub 2011 Jun 3.

PMID:
21642514
39.

Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis.

Holstein SA, Kuder CH, Tong H, Hohl RJ.

Lipids. 2011 Oct;46(10):907-21. doi: 10.1007/s11745-011-3572-y. Epub 2011 Jun 2.

40.

Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation.

Weivoda MM, Hohl RJ.

Endocrinology. 2011 Aug;152(8):3113-22. doi: 10.1210/en.2011-0016. Epub 2011 May 17.

PMID:
21586555
41.

The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation.

Weivoda MM, Hohl RJ.

J Cell Biochem. 2011 Jun;112(6):1506-13. doi: 10.1002/jcb.23087.

PMID:
21503955
42.

Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.

Wasko BM, Dudakovic A, Hohl RJ.

J Pharmacol Exp Ther. 2011 May;337(2):540-6. doi: 10.1124/jpet.110.175521. Epub 2011 Feb 18.

PMID:
21335425
43.

Biologically active biotin derivatives of schweinfurthin F.

Ulrich NC, Kuder CH, Hohl RJ, Wiemer DF.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6716-20. doi: 10.1016/j.bmcl.2010.08.143. Epub 2010 Sep 6.

PMID:
20869871
44.

Synthesis and biological evaluation of a series of aromatic bisphosphonates.

Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF.

Bioorg Med Chem. 2010 Oct 15;18(20):7212-20. doi: 10.1016/j.bmc.2010.08.036. Epub 2010 Aug 19.

PMID:
20832326
45.
46.

Fluorescent schweinfurthin B and F analogs with anti-proliferative activity.

Topczewski JJ, Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF.

Bioorg Med Chem. 2010 Sep 15;18(18):6734-41. doi: 10.1016/j.bmc.2010.07.056. Epub 2010 Jul 29.

47.

Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration.

Dudakovic A, Tong H, Hohl RJ.

Invest New Drugs. 2011 Oct;29(5):912-20. doi: 10.1007/s10637-010-9446-y. Epub 2010 May 18.

PMID:
20480384
48.

Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure.

Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF.

Bioorg Med Chem. 2010 Feb 15;18(4):1676-83. doi: 10.1016/j.bmc.2009.12.063. Epub 2010 Jan 4.

49.

Quantitative determination of geranyl diphosphate levels in cultured human cells.

Holstein SA, Tong H, Kuder CH, Hohl RJ.

Lipids. 2009 Nov;44(11):1055-62. doi: 10.1007/s11745-009-3355-x. Epub 2009 Oct 24.

PMID:
19856009
50.

Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Holstein SA, Tong H, Hohl RJ.

Leuk Res. 2010 Mar;34(3):344-51. doi: 10.1016/j.leukres.2009.06.035. Epub 2009 Jul 30.

Supplemental Content

Support Center